

NIGM

Non-invasive Prenatal Testing (NIPT) of GeneMind

Simple

Test from a tube of 10ml maternal blood sample as early as 9 gestational weeks

Accurate

Proven >99% sensitivity based on a test of more than 20,000 pregnancies.

Fast & Convenient

- Quick test from sample preparation to issue report within 24 hours
- Simplified operation: Automated and localized data analysis and report

Flexibility

Compatible with most standard NGS library prep kits and bioinformatics tools




Introduction to NIGM

Noninvasive prenatal testing (NIPT) performed with NGS sequencing system GenoLab M*, FASTASeq 300* and SURFSeq 5000* provides reliable screening results for fetal chromosomal aneuploidies as early as 9 gestational weeks—from a single tube of 10 mL maternal blood. Support G tube (Provided by GeneMind) and Streck Tube.

Parameter		NIPT Basic	NIPT Standard	NIPT Plus	NIPT Pro
Sample Volume		10 mL of a single tube of maternal blood			
Library preparation		PCR			
Method		Low-pass whole genome sequencing			
No. of samples per run(1 PC +1 NC included)	GenoLab M*	1 FCM : 48 2 FCM/1 FCH : 96 1 FCM+1 FCH : 144 2 FCH : 192	1 FCM : 32 2 FCM/1 FCH : 64 1 FCM+1 FCH : 96 2 FCH : 128	1 FCM : 24 2 FCM/1 FCH : 48 1 FCM+1 FCH : 72 2 FCH : 96	1 FCM : 10 2 FCM/1 FCH : 20 1 FCM+1 FCH : 30 2 FCH : 40
	FASTASeq 300*	1 FCH : 48 1 FCM : 24	1 FCH : 32 1 FCM : 16	1 FCH : 24 1 FCM : 12	1 FCH : 10 1 FCM : 5
	SURFSeq 5000*	1 FCH : 250	1 FCH : 160	1 FCH : 96	1 FCH : 64
Read length		SE 75 on GenoLab M* and FASTASeq 300* SE 50 on SURFSeq 5000*			
Average Unique Reads / sample	GenoLab M* and FASTASeq 300*	≥3.5 M	≥5 M	≥7 M	≥16 M
	SURFSeq 5000*	≥5 M	≥7 M	≥12 M	≥20 M
Turnaround time		25 h on GenoLab M*, 21.5 h on FASTASeq 300*, and 26 h on SURFSeq 5000*			
Report generation		Local analysis and report system			

NIPT Basic	NIPT Standard
<ul style="list-style-type: none"> ▶ Trisomies 21/18/13 ▶ Sex identification, fetal fraction estimation 	<ul style="list-style-type: none"> ▶ Trisomies 21/18/13 ▶ 6 Sex Chromosome Aneuploidies (SCAs) (XO/XXX/XXY/XYY/XO+XY/XXX+XY) ▶ Other 19 autosomal Aneuploidies ▶ Sex identification, fetal fraction estimation
NIPT Plus	NIPT Pro
<ul style="list-style-type: none"> ▶ Trisomies 21/18/13 ▶ 6 Sex Chromosome Aneuploidies (SCAs) (XO/XXX/XXY/XYY/XO+XY/XXX+XY) ▶ Other 19 autosomal Aneuploidies ▶ 60 Microdeletion/duplications syndromes ▶ Sex identification, fetal fraction estimation 	<ul style="list-style-type: none"> ▶ Trisomies 21/18/13 ▶ 6 Sex Chromosome Aneuploidies (SCAs) (XO/XXX/XXY/XYY/XO+XY/XXX+XY) ▶ Other 19 autosomal Aneuploidies ▶ 90 Microdeletion/duplications syndromes (Including Di-George Syndrome) ▶ Sex identification, fetal fraction estimation


Support Both Manual and Automated Solutions



	G Tube	Streck Tube	MrLH-96		GenoLab M*	AIRS	
Automated workflow							25 hours in total
	2 h		6 h	2.5 h	13 h	1.5 h	
	G Tube	Streck Tube			FASTASeq 300*	AIRS	
Manual workflow							21.5 hours in total
	2 h		8 hours (at least 3 technicians)	2.5 h	7.5 h	1.5 h	
	G Tube	Streck Tube	MrLH-96		SURFSeq 5000*	AIRS	
Automated workflow							26 hours in total
	2 h		6 h	2.5 h	14 h	1.5 h	

- ▶ G Tube: provided and validated by GeneMind
- ▶ MrLH-96: Automated Sample Preparation System, consumables (tips and plates) provided and validated by GeneMind
- ▶ GenoLab M*, FASTASeq 300* and SURFSeq 5000* : sequencing device from GeneMind
- ▶ AIRS: Automated Integrated Report Server provided and validated

The Test Workflow and Advantages




1. non-complimentary

● cfDNA Extraction

During pregnancy, cell-free DNA (cfDNA) fragments originate from both the mother and fetus are present in maternal blood circulation. Cell-free fetal DNA (cffDNA) is present only as a minority component of the total cfDNA in maternal plasma, which poses a significant technical challenge for some NIPT detection methods.

Using paramagnetic particle method, our cfDNA extraction process is compatible with a variety of blood collection vessels with the requirement of as little as 200uL plasma. The success rate of cfDNA extraction is above 99.9% if the maternal plasma meets the sampling standard.




● Library preparation

● Low-input

The success rate of cfDNA library construction is above 99.9% even if the amount of cfDNA is as little as 100pg.

● High conversion efficiency

With significant enrichment effect of fetal concentration, the library yield is sufficient for multiple validation and long-term storage.



● Sequencing

We conduct sequencing on High-throughput DNA Sequencing Platform GenoLab M*.


Accurate

- High-fidelity sequencing chemistry and unique optical system

Cost Effective

- Competitive instrument and reagent kit prices
- Single-flow cell and dual-flow cell mode give customer more control over per-sample cost

● Automated Bioinformatics Analysis and Report



Sample Requirement


Sample Type	Quantity	Requirements	Shipment
Plasma	2ml (4 tubes required)	Stored in 1.5ml Eppendorf tubes, and sealed with 1cm wide parafilm	Stored at -80 °C, shipped with dry ice within one week. Shipping with dry ice can last up to seven days.
Maternal Blood	10ml	Gently invert the tube ten times immediately after blood sampling	Stored and shipped between 6~35 °C within 4 days. Keep the tubes upright during shipping

Clinical Validation



Trisomy	Positive ²	Sensitivity	Specificity	PPV	NPV
T21	108	100%	99.92%	95.58%	100.00%
T18	25	100%	99.85%	73.53%	100.00%
T13	25	100%	99.89%	78.13%	100.00%
SCA	62	93.55%	99.47%	64.44%	99.93%
CNV	27	55.56%	99.87%	65.22%	99.80%
Total	247	100%	99.82%	93.64%	99.82%

2. validated by more than 20,000 retrospective clinical samples

Performance in Sex Identification, Fetal Fraction Estimation and SCAs Detections



Fetal fraction estimation is highly consistent with existing products



About GeneMind

GeneMind Biosciences Co., Ltd. (hereinafter referred to as 'GeneMind') was founded in 2012 and is headquartered in Luohu, Shenzhen. Its facility includes more than 8,000 square meters of research and development laboratories and GMP production lines.

From the company's inception, GeneMind aimed at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostic platform. GeneMind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions. We has launched high-throughput sequencing platform GenoLab M*, FASTASeq 300*, and SURFSeq 5000*, which can provide 'instrument-reagent-chip-software' full-platform solutions. With nearly 200 technical patents, covering mainland China, Hong Kong, Europe, and the United States, GeneMind is one of the few companies in the world that possess core DNA sequencing technologies and independent products.

After several years of hard work, GeneMind has mastered the key technologies of the DNA sequencing, and realized production of core materials such as enzymes, nucleic acids, dyes, and biochips in China, providing research and medical institutions with competent domestically produced sequencing solutions.



*Unless otherwise informed, GeneMind sequencing platform and related sequencing reagents are not available in the USA, Canada, Australia, Japan, Singapore, Western Europe, Southern Europe and Nordic countries yet.

